37 studies found for:    Gilead | hepatitis c | Phase 3
Show Display Options
Rank Status Study
1 Completed
Has Results
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Peg-IFN
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2012
Primary Completion: October 2014
2 Recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: September 2015
Primary Completion: September 2016
3 Not yet recruiting Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2016
Primary Completion: December 2016
4 Active, not recruiting Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: February 2015
Primary Completion: March 2016
5 Not yet recruiting HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
Conditions: Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: E/C/F/TAF;;   Drug: Ledipasvir-Sofosbuvir
Phase: Phase 3
Sponsor/Collaborators: Ottawa Hospital Research Institute;   Gilead Sciences;   CIHR Canadian HIV Trials Network
Study Start: April 2016
Primary Completion: February 2017
6 Recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
Condition: Hepatitis C Virus Infection
Intervention: Drug: LDV/SOF
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: January 2017
7 Active, not recruiting Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection.
Condition: Hepatitis C Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: June 2015
Primary Completion: March 2016
8 Recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: November 2015
Primary Completion: January 2017
9 Recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/GS-9857;   Drug: Placebo
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: November 2015
Primary Completion: January 2017
10 Recruiting Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: November 2015
Primary Completion: January 2017
11 Recruiting Safety and Efficacy of SOF/VEL/GS-9857 FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: December 2016
12 Recruiting Safety and Efficacy of SOF/VEL/GS-9857 FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/GS-9857;   Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: December 2015
Primary Completion: December 2016
13 Recruiting Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: LDV/SOF;   Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: April 2016
Primary Completion: May 2017
14 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: April 2016
Primary Completion: September 2017
15 Completed
Has Results
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2012
Primary Completion: November 2013
16 Active, not recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: July 2015
Primary Completion: April 2016
17 Completed
Has Results
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Chronic Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: Sofosbuvir;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: January 2013
Primary Completion: April 2014
18 Completed
Has Results
Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C Virus
Interventions: Drug: SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: March 2013
Primary Completion: May 2014
19 Completed
Has Results
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: May 2013
Primary Completion: December 2013
20 Completed
Has Results
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection
Condition: Chronic Hepatitis C Virus
Interventions: Drug: LDV/SOF;   Drug: RBV
Phase: Phase 3
Sponsor: Gilead Sciences
Study Start: January 2013
Primary Completion: November 2013

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years